204 related articles for article (PubMed ID: 32276963)
1. CXL146, a Novel 4
Bian T; Tagmount A; Vulpe C; Vijendra KC; Xing C
Mol Pharmacol; 2020 Jun; 97(6):402-408. PubMed ID: 32276963
[TBL] [Abstract][Full Text] [Related]
2. Ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017): a novel scaffold that resensitizes multidrug resistant leukemia cells to chemotherapy.
Das SG; Hermanson DL; Bleeker N; Lowman X; Li Y; Kelekar A; Xing C
ACS Chem Biol; 2013 Feb; 8(2):327-35. PubMed ID: 23102022
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase IIβ downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia.
Hermanson DL; Das SG; Li Y; Xing C
Mol Pharmacol; 2013 Aug; 84(2):236-43. PubMed ID: 23696245
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and its analogues.
Das SG; Srinivasan B; Hermanson DL; Bleeker NP; Doshi JM; Tang R; Beck WT; Xing C
J Med Chem; 2011 Aug; 54(16):5937-48. PubMed ID: 21780800
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
Aridoss G; Zhou B; Hermanson DL; Bleeker NP; Xing C
J Med Chem; 2012 Jun; 55(11):5566-81. PubMed ID: 22582991
[TBL] [Abstract][Full Text] [Related]
6. Bioreductive activation of mitoxantrone by NADPH cytochrome P450 reductase does not change its apoptotic stimuli properties in regard to sensitive and multidrug resistant leukaemia HL60 cells.
Kostrzewa-Nowak D; Tarasiuk J
Eur J Pharmacol; 2013 Dec; 721(1-3):141-50. PubMed ID: 24076328
[TBL] [Abstract][Full Text] [Related]
7. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D
Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232
[TBL] [Abstract][Full Text] [Related]
8. A novel SERCA inhibitor demonstrates synergy with classic SERCA inhibitors and targets multidrug-resistant AML.
Bleeker NP; Cornea RL; Thomas DD; Xing C
Mol Pharm; 2013 Nov; 10(11):4358-66. PubMed ID: 24079514
[TBL] [Abstract][Full Text] [Related]
9. Exploring the Structure-Activity Relationship and Mechanism of a Chromene Scaffold (CXL Series) for Its Selective Antiproliferative Activity toward Multidrug-Resistant Cancer Cells.
Bian T; Chandagirikoppal Vijendra K; Wang Y; Meacham A; Hati S; Cogle CR; Sun H; Xing C
J Med Chem; 2018 Aug; 61(15):6892-6903. PubMed ID: 29995404
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen-induced cytotoxicity in breast cancer cells is mediated by glucose-regulated protein 78 (GRP78) via AKT (Thr308) regulation.
Pujari R; Jose J; Bhavnani V; Kumar N; Shastry P; Pal JK
Int J Biochem Cell Biol; 2016 Aug; 77(Pt A):57-67. PubMed ID: 27262235
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
Das SG; Doshi JM; Tian D; Addo SN; Srinivasan B; Hermanson DL; Xing C
J Med Chem; 2009 Oct; 52(19):5937-49. PubMed ID: 19743858
[TBL] [Abstract][Full Text] [Related]
12. Correction to "CXL146, a Novel 4
Mol Pharmacol; 2020 Aug; 98(2):182. PubMed ID: 32718917
[No Abstract] [Full Text] [Related]
13. Different Roles of GRP78 on Cell Proliferation and Apoptosis in Cartilage Development.
Xiong Z; Jiang R; Li X; Liu Y; Guo F
Int J Mol Sci; 2015 Sep; 16(9):21153-76. PubMed ID: 26370957
[TBL] [Abstract][Full Text] [Related]
14. 4H-Chromene-based anticancer agents towards multi-drug resistant HL60/MX2 human leukemia: SAR at the 4th and 6th positions.
Puppala M; Zhao X; Casemore D; Zhou B; Aridoss G; Narayanapillai S; Xing C
Bioorg Med Chem; 2016 Mar; 24(6):1292-7. PubMed ID: 26867486
[TBL] [Abstract][Full Text] [Related]
15. A peptide derived from phage display library exhibits anti-tumor activity by targeting GRP78 in gastric cancer multidrug resistance cells.
Kang J; Zhao G; Lin T; Tang S; Xu G; Hu S; Bi Q; Guo C; Sun L; Han S; Xu Q; Nie Y; Wang B; Liang S; Ding J; Wu K
Cancer Lett; 2013 Oct; 339(2):247-59. PubMed ID: 23792224
[TBL] [Abstract][Full Text] [Related]
16. GRP78-targeting subtilase cytotoxin sensitizes cancer cells to photodynamic therapy.
Firczuk M; Gabrysiak M; Barankiewicz J; Domagala A; Nowis D; Kujawa M; Jankowska-Steifer E; Wachowska M; Glodkowska-Mrowka E; Korsak B; Winiarska M; Golab J
Cell Death Dis; 2013 Jul; 4(7):e741. PubMed ID: 23887632
[TBL] [Abstract][Full Text] [Related]
17. Mechanism study of peptide GMBP1 and its receptor GRP78 in modulating gastric cancer MDR by iTRAQ-based proteomic analysis.
Wang X; Li Y; Xu G; Liu M; Xue L; Liu L; Hu S; Zhang Y; Nie Y; Liang S; Wang B; Ding J
BMC Cancer; 2015 May; 15():358. PubMed ID: 25943993
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of CEMIP suppresses proliferation and induces apoptosis in colorectal cancer cells: downregulation of GRP78 and attenuation of unfolded protein response.
Liang G; Fang X; Yang Y; Song Y
Biochem Cell Biol; 2018 Jun; 96(3):332-341. PubMed ID: 29024602
[TBL] [Abstract][Full Text] [Related]
19. Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat.
Kahali S; Sarcar B; Fang B; Williams ES; Koomen JM; Tofilon PJ; Chinnaiyan P
Neoplasia; 2010 Jan; 12(1):80-6. PubMed ID: 20072656
[TBL] [Abstract][Full Text] [Related]
20. Association between the unfolded protein response, induced by 2-deoxyglucose, and hypersensitivity to cisplatin: a mechanistic study employing molecular genomics.
Gaddameedhi S; Chatterjee S
J Cancer Res Ther; 2009 Sep; 5 Suppl 1():S61-6. PubMed ID: 20009298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
